Vascular Occlusion From Filler: Warning Signs and What to Do

Vascular occlusion is what happens when filler is unintentionally injected into a blood vessel: the vessel becomes blocked and the tissue it supplies loses its blood flow.

FDA calls unintentional injection into a blood vessel the most concerning risk associated with the use of dermal fillers.

It is rare, FDA says, but it can cause tissue death (necrosis), vision problems including blindness, and stroke — and the damage may be permanent.

Product labels carry the same warning into the treatment room.

The Restylane Kysse instructions for use warn that injection into vessels can cause embolization, occlusion, ischemia or infarction, and that localized superficial necrosis and scarring may occur after injection in or near vessels, "such as in the lips."

Where does this sit in the wider filler risk picture?

FDA's list of rare reported filler risks includes anaphylaxis, migration, permanent hard nodules, blindness, stroke and death.

Two of those — vision problems including blindness and stroke — are outcomes FDA says unintentional injection into a blood vessel can cause.

This page covers that emergency; our dermal fillers guide covers the treatments, products and costs.

How often does it happen?

There is no single universal rate — the numbers that exist come from specific self-reported or single-clinic datasets.

In a 2021 JAMA Dermatology study, 370 US board-certified dermatologists reporting 1.7 million syringes described 1 occlusion per 6,410 one-mL syringes injected with needles and 1 per 40,882 with cannulas, and 85% of the occlusions they reported left no long-term effects.

One Japanese clinic group's review of 290,307 hyaluronic acid filler injections found 12 serious complications — 10 of them vascular obstructions — an incidence of 0.0041%, with 8 of the 10 vascular events following forehead injection.

A clinical review describes a sequence of signs when hyaluronic acid filler compromises a vessel: skin blanching (skin that turns pale or white), a lace-like purple pattern known as livedo reticularis, slow capillary refill (color returning slowly after a press on the skin) and a dusky blue-red discoloration.

Days later, the same review describes blister formation and finally tissue slough, where the surface tissue breaks down.

The true incidence is unknown, that review notes, because of under-reporting.

Ordinary healing looks different.

In the Restylane Kysse pivotal trial, the most common diary-reported lip reactions after initial treatment were swelling (90.2%), tenderness (87.4%) and bruising (85.8%), and most were tolerable and lasted less than 2 weeks.

FDA lists swelling, tenderness and bruising among the common filler risks; the occlusion signs are changes beyond them — unusual pain, skin color change and vision symptoms.

The first steps belong to the person holding the needle.

FDA tells injectors to know the signs of intravascular injection, to have an updated plan detailing how the patient will be treated should it occur — on-site treatment and/or immediate referral — and to stop injecting at signs such as skin blanching, vision change, stroke signs or unusual pain.

For the person in the chair, the move FDA describes is the one in the list above: immediate medical attention, not a wait-and-see few days.

Vision changes and stroke signs are emergencies from the first minute.

What does treatment look like?

For hyaluronic acid filler, expert reviews list prompt recognition and immediate hyaluronidase as the mainstay.

Post-marketing reports for Restylane Kysse describe the same pattern: among the most commonly reported serious events were ischemia and necrosis, and those cases were treated with measures including hyaluronidase.

These are spontaneous reports, so they show what was done, not how often it happens.

What role does speed play?

Expert reviews put prompt recognition first among the mainstays of treatment, and the 2024 review shows what the stakes are: of the 318 cases reporting visual outcomes, 6.0% recovered vision completely, 25.8% improved partially and 68.2% did not recover.

Published case reviews of filler-related vision loss rank the same sites at the top.

A 2015 review of 98 published cases found the glabella (38.8%), nose (25.5%), nasolabial fold (13.3%) and forehead (12.2%) were the highest-risk injection sites, and most cases of vision loss did not recover.

A 2019 update covering 48 new published cases put the nose first (56.3%), ahead of the glabella (27.1%), forehead (18.8%) and nasolabial fold (14.6%); hyaluronic acid filler was involved in 81.3%, and only 20.8% had complete recovery of vision.

A 2024 review of 365 further cases again put the nose first (40.6%), followed by the forehead (27.7%) and glabella (19.0%), with hyaluronic acid involved in 79.6%.

These are shares of published case reports, not rates — a case series cannot tell you the chance at your own appointment.

The pattern is consistent enough that FDA's approval record is worth knowing: no US filler is FDA-approved for the nose, glabella or forehead, and FDA's general filler page lists all three among the uses that are not approved.

Tissue occlusion is a wider map than vision loss.

In the dermatologist survey behind the numbers above, nasolabial folds and lips were the sites most likely to be occluded, and the Restylane Kysse label specifically names the lips as a place where necrosis and scarring can occur near vessels.

The forehead shows up in the single-clinic data too: 8 of the 10 vascular events in the Japanese chain's review followed forehead injection.

Considering nose filler?

Our nose filler risks page gathers the nose numbers in one place.

FDA's wording for injectors is to know the signs of intravascular injection and to have an updated plan detailing how the patient will be treated should it occur — on-site treatment and/or immediate referral.

FDA does not name the drug.

The expectation that the drug on hand should be hyaluronidase comes from the professional literature: expert reviews list prompt recognition and immediate hyaluronidase as the mainstay of treating hyaluronic acid filler occlusion, and recommend emergency preparedness — a "filler crash cart" and an in-office action protocol with the agents readily available.

The tool has limits worth knowing.

Hyaluronidase breaks down hyaluronic acid fillers only — not silicone, and not filler materials such as calcium hydroxylapatite (Radiesse) or poly-L-lactic acid (Sculptra).

In the non-emergency setting, Cleveland Clinic says dissolving usually takes one to two visits with full results in up to two weeks, and Allergan's safety information states that the effectiveness of removal of any dermal filler has not been studied.

The drug's own label lists no filler indication: hyaluronidase products such as Hylenex are FDA-approved only as an adjuvant for subcutaneous fluid administration, to increase the dispersion and absorption of other injected drugs, and in subcutaneous urography.

Dissolving filler — in an emergency or electively — is an off-label use.

How the enzyme works, what it costs and the allergy questions it raises are covered in our hyaluronidase guide.

FDA says filler injection should be considered a medical procedure, not a cosmetic treatment, and advises choosing a licensed health care provider with dermatology or plastic-surgery experience who is trained in filler injection.

The emergency this page describes is the reason that sentence is not boilerplate.

Four questions put it to work.

Answers should be specific: the product name, the protocol, the drug on the crash cart.

If they are vague, keep looking.

Our guide to how to choose a med spa injector covers credentials, supervision and the other checks worth running first.